Aprea Therapeutics, Inc

(NASDAQ:APRE)

Latest On Aprea Therapeutics, Inc (APRE):

Date/Time Type Description Signal Details
2023-05-15 19:16 ESTNewsAprea Therapeutics GAAP EPS of -$1.34N/A
2023-04-07 00:02 ESTNewsAprea Therapeutics (APRE) Investor Presentation - SlideshowN/A
2023-03-31 15:24 ESTNewsAprea Therapeutics GAAP EPS of -$0.92 beats by $2.30N/A
2023-03-02 11:37 ESTNewsAprea Therapeutics regains Nasdaq compliance with minimum bid price requirementN/A
2023-02-23 10:23 ESTNewsAprea Therapeutics dips after pricing $5.5M stock offeringN/A
2023-02-22 21:46 ESTNewsAprea Therapeutics stock slides 20% after announcing stock offeringN/A
2023-02-13 15:30 ESTNewsAprea Therapeutics announces one-for-twenty reverse stock split to meet Nasdaq complianceN/A
2023-01-30 09:50 ESTNewsAprea Therapeutics appoints John Hamill as CFON/A
2022-11-09 18:23 ESTNewsAprea Therapeutics GAAP EPS of -$0.12 misses by $0.03N/A
2022-08-11 21:06 ESTNewsAprea TherapeuticsEPS of -$4.34N/A
2022-07-08 13:26 ESTNewsAprea Therapeutics surges on heavy volume; Wedbush initiates at outperform, $3 PTN/A
2022-05-17 01:34 ESTNewsAprea Therapeutics GAAP EPS of -$0.36 beats by $0.02N/A
2022-03-16 21:55 ESTNewsAprea Therapeutics GAAP EPS of -$0.36 beats by $0.08N/A
2021-12-09 13:56 ESTNewsAprea Therapeutics gains 9% on FDA removal of clinical hold on eprenetapoptN/A
2021-11-09 01:22 ESTNewsAprea Therapeutics EPS beats by $0.01N/A
2021-09-30 06:25 ESTNewsCNTG, APRE, LNDC and ERYP among after hours moversN/A
2021-09-27 09:58 ESTNewsWarning: APRE has been downgraded to Very BearishN/A
2021-09-22 17:24 ESTNewsWarning: APRE has been downgraded to Very Bearish.N/A
2021-09-22 17:24 ESTNewsAprea to present phase 1/2 trial data of eprenetapopt-Keytruda combo to treat tumorsN/A
2021-09-22 17:22 ESTNewsCRVS, APRE, GDS and OYST among after hours moversN/A
2021-09-22 17:21 ESTNewsAprea gains ahead of data presentation for drug combination in solid tumorsN/A
2021-09-22 17:21 ESTNewsAprea presents Phase I/II data for eprenetapopt/ Keytruda combo in solid tumorsN/A
2021-09-22 17:21 ESTNewsAPRE, GMAB, VRCA and CRVS among after hours moversN/A
2021-08-13 06:38 ESTNewsAprea Therapeutics EPS beats by $0.02N/A
2021-08-05 19:39 ESTNewsAprea shares slide 11% after partial clinical hold on myeloid malignancy programsN/A
2021-07-22 15:49 ESTNewsAprea Therapeutics' shares soar on positive early-stage leukemia study dataN/A
2021-07-22 15:49 ESTNewsOpthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losersN/A
2021-07-22 15:47 ESTNewsAprea releases positive phase 2 results on eprenetapopt for MDS, leukemiaN/A
2021-04-08 21:59 ESTNewsAprea Therapeutics shares rise after leukemia treatment gets FDA orphan drug statusN/A
2021-03-18 15:07 ESTFinancialsCompany financials have been released.Neutral
2021-03-18 11:10 ESTFinancialsCompany financials have been released.Neutral
2021-03-18 07:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $8 to $7.5.Neutral
2021-03-17 16:02 ESTNewsAprea Therapeutics EPS misses by $0.10N/A
2021-03-17 15:21 ESTEarnings EstimateAn EPS average of -$1.67 is estimated for the 2022 year.Sell
2021-03-17 15:21 ESTEarnings EstimateAn EPS average of -$0.52 is estimated for the quarter ending on June 30, 2021.Buy
2021-02-16 21:35 ESTNewsAssessing Aprea TherapeuticsN/A
2021-01-29 02:21 ESTAnalyst RatingThe Analyst Target Price has increased from $7.4 to $8.Buy
2021-01-20 14:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.33 to $7.4.Neutral
2021-01-19 22:20 ESTNewsAprea Therapeutics (APRE) Presents at J.P. Morgan Healthcare Conference 2021 - SlideshowN/A
2021-01-12 18:09 ESTNewsAprea Therapeutics provides financial updatesN/A
2020-12-30 06:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.83 to $11.33.Neutral
2020-12-29 14:01 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.17 to $19.83.Neutral
2020-12-28 19:14 ESTNewsAprea's eprenetapopt flunks late-stage cancer study, shares down 73%N/A
2020-12-28 19:13 ESTNewsAprea’s cancer therapy fails in late-stage studyN/A
2020-12-17 06:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $37 to $36.17.Neutral
2020-12-08 14:41 ESTAnalyst RatingThe Analyst Target Price has increased from $35.8 to $37.Buy
2020-12-04 18:44 ESTFinancialsCompany financials have been released.Neutral
2020-12-02 12:42 ESTNewsAprea's eprenetapopt Fast Track'd for type of blood cancerN/A
2020-11-27 00:11 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 14:43 ESTFinancialsCompany financials have been released.Neutral

About Aprea Therapeutics, Inc (APRE):

Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

APRE Quotes by TradingView

See Advanced Chart

General

  • Name Aprea Therapeutics, Inc
  • Symbol APRE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 13
  • Fiscal Year EndDecember
  • IPO Date2019-10-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.aprea.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.42
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.07
  • Next Year EPS Estimate -$1.84
  • Next Quarter EPS Estimate -$0.55
  • Return on Assets -29%
  • Return on Equity -53%
  • Earnings Per Share -$22.79
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 127.54 million
  • EBITDA -18167488
  • Analyst Target Price $7.5
  • Book Value Per Share -$83.99
View More

Share Statistics

  • Shares Outstanding 21.19 million
  • Shares Float 14.21 million
  • % Held by Insiders 1291%
  • % Held by Institutions 87.8%
  • Shares Short 1.43 million
  • Shares Short Prior Month 1.89 million
  • Short Ratio 0.77
  • Short % of Float 24%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $41.12
  • 52 Week Low $4.66
  • 50 Day Moving Average 6.25
  • 200 Day Moving Average 17.47
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aprea Therapeutics, Inc (APRE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aprea Therapeutics, Inc (APRE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A-$0.73-$0.64-14.06%
2020-09-302020-11-05$N/A-$0.58-$0.7623.73%
2020-06-302020-08-11$N/A-$0.78-$0.60-29.46%
2020-03-312020-05-15$N/A-$0.45-$0.5720.7%
2019-12-312020-03-26$N/A-$0.64-$0.41-56.06%
2019-09-302019-11-14$N/A-$5.29-$5.676.76%

Aprea Therapeutics, Inc (APRE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Aprea Therapeutics, Inc (APRE) Chart:

Aprea Therapeutics, Inc (APRE) News:

Below you will find a list of latest news for Aprea Therapeutics, Inc (APRE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aprea Therapeutics, Inc (APRE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Aprea Therapeutics, Inc (APRE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000752/0000905148-20-000752-index.htm
2019-11-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000031506619001759/0000315066-19-001759-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000031506620000788/0000315066-20-000788-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000089924319025205/0000899243-19-025205-index.htm
2020-06-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000730/0000905148-20-000730-index.htm
2020-06-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000731/0000905148-20-000731-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000732/0000905148-20-000732-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000733/0000905148-20-000733-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000747/0000905148-20-000747-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000749/0000905148-20-000749-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000750/0000905148-20-000750-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000751/0000905148-20-000751-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820000752/0000905148-20-000752-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820001029/0000905148-20-001029-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820001030/0000905148-20-001030-index.htm
2020-09-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820001048/0000905148-20-001048-index.htm
2020-09-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000090514820001049/0000905148-20-001049-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465919053617/0001104659-19-053617-index.htm
2019-10-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000110465919054651/0001104659-19-054651-index.htm
2019-10-17SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1781983/000110465919054703/0001104659-19-054703-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465919064230/0001104659-19-064230-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1781983/000110465919064239/0001104659-19-064239-index.htm
2019-11-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1781983/000110465919065133/0001104659-19-065133-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465919073042/0001104659-19-073042-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920003469/0001104659-20-003469-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920019740/0001104659-20-019740-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920020754/0001104659-20-020754-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038557/0001104659-20-038557-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038875/0001104659-20-038875-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038879/0001104659-20-038879-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038880/0001104659-20-038880-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038881/0001104659-20-038881-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920038882/0001104659-20-038882-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920043126/0001104659-20-043126-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920062070/0001104659-20-062070-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920064447/0001104659-20-064447-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920064448/0001104659-20-064448-index.htm
2020-05-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1781983/000110465920064979/0001104659-20-064979-index.htm
2020-06-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1781983/000110465920073489/0001104659-20-073489-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920078182/0001104659-20-078182-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920093306/0001104659-20-093306-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920106537/0001104659-20-106537-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920109852/0001104659-20-109852-index.htm
2020-10-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1781983/000110465920113115/0001104659-20-113115-index.htm
2020-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000110465920113186/0001104659-20-113186-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1781983/000110465920121825/0001104659-20-121825-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000112329219001212/0001123292-19-001212-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000112329220000665/0001123292-20-000665-index.htm
2020-07-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000112329220000973/0001123292-20-000973-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018070/0001140361-19-018070-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018071/0001140361-19-018071-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018074/0001140361-19-018074-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018075/0001140361-19-018075-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018077/0001140361-19-018077-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018079/0001140361-19-018079-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018081/0001140361-19-018081-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018083/0001140361-19-018083-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018086/0001140361-19-018086-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018087/0001140361-19-018087-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018090/0001140361-19-018090-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114036119018091/0001140361-19-018091-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000114420419047721/0001144204-19-047721-index.htm
2019-10-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000114420419047722/0001144204-19-047722-index.htm
2019-10-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000117266119002041/0001172661-19-002041-index.htm
2019-10-17SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1781983/000119312519269398/0001193125-19-269398-index.htm
2020-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120031545/0001209191-20-031545-index.htm
2020-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120031546/0001209191-20-031546-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120036845/0001209191-20-036845-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120036847/0001209191-20-036847-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120037714/0001209191-20-037714-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1781983/000120919120037715/0001209191-20-037715-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1781983/000127417320000087/0001274173-20-000087-index.htm
2020-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1781983/000155837020003257/0001558370-20-003257-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1781983/000155837020004645/0001558370-20-004645-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1781983/000155837020004661/0001558370-20-004661-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1781983/000155837020006741/0001558370-20-006741-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1781983/000155837020010336/0001558370-20-010336-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/0001558370-20-013179-index.htm

Aprea Therapeutics, Inc (APRE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aprea Therapeutics, Inc (APRE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1291%
Institutional Ownership: 8780%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-07CHRISTIAN S SCHADEPresident & CEOBuy1,000.0015.0015,000.001,000.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018070/0001140361-19-018070-index.htm
2020-10-055AM Ventures IV, L.P.InsiderSell175,000.0025.304,427,500.00138,497.00https://www.sec.gov/Archives/edgar/data/1781983/000110465920113186/0001104659-20-113186-index.htm
2020-06-165AM Ventures IV, L.P.10% Share HolderSell115,357.0033.303,841,388.101,823,192.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120037714/0001209191-20-037714-index.htm
2020-06-16SCOTT M ROCKLAGEDirectorSell115,357.0033.303,841,388.101,823,192.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120037715/0001209191-20-037715-index.htm
2020-06-115AM Ventures IV, L.P.10% Share HolderSell235,200.0028.756,762,635.041,938,549.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120036845/0001209191-20-036845-index.htm
2020-06-11SCOTT M ROCKLAGEDirectorSell235,200.0028.756,762,635.041,938,549.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120036847/0001209191-20-036847-index.htm
2020-07-07Investments AB KDev10% Share HolderSell241,703.0034.558,350,838.651,992,586.00https://www.sec.gov/Archives/edgar/data/1781983/000112329220000973/0001123292-20-000973-index.htm
2019-10-07Eyal C. AttarSVP, Chief Medical OfficerBuy200.0015.003,000.00200.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018074/0001140361-19-018074-index.htm
2020-05-195AM Ventures IV, L.P.10% Share HolderSell244,800.0035.158,604,720.002,173,748.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120031545/0001209191-20-031545-index.htm
2020-05-19SCOTT M ROCKLAGEDirectorSell244,800.0035.158,604,720.002,173,748.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120031546/0001209191-20-031546-index.htm
2020-04-13Investments AB KDev10% Share HolderSell210,548.0031.256,579,625.002,234,289.00https://www.sec.gov/Archives/edgar/data/1781983/000112329220000665/0001123292-20-000665-index.htm
2019-10-07Redmile Group, LLC10% Share HolderBuy400,000.0015.006,000,000.002,268,718.00https://www.sec.gov/Archives/edgar/data/1781983/000114420419047722/0001144204-19-047722-index.htm
2019-10-07HealthCap VII, L.P.10% Share HolderBuy266,667.0015.004,000,005.002,366,104.00https://www.sec.gov/Archives/edgar/data/1781983/000089924319025205/0000899243-19-025205-index.htm
2019-10-07Johan ChristensonDirectorBuy266,667.0015.004,000,005.002,366,104.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018087/0001140361-19-018087-index.htm
2019-10-07Scott M CoianteSVP, Chief Financial OfficerBuy2,500.0015.0037,500.002,500.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018071/0001140361-19-018071-index.htm
2019-10-07Bernd R. SeizingerDirectorBuy263,970.000.0718,477.90263,970.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018086/0001140361-19-018086-index.htm
2020-06-165AM Ventures IV, L.P.10% Share HolderSell19,836.0033.30660,538.80313,497.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120037714/0001209191-20-037714-index.htm
2019-10-075AM Ventures IV, L.P.10% Share HolderBuy333,333.0015.004,999,995.00333,333.00https://www.sec.gov/Archives/edgar/data/1781983/000110465919053617/0001104659-19-053617-index.htm
2019-10-07V Luxco S.a r.l. Versant10% Share HolderBuy333,333.0015.004,999,995.00333,333.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018090/0001140361-19-018090-index.htm
2019-10-07Versant Vantage I, L.P.10% Share HolderBuy333,333.0015.004,999,995.00333,333.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018091/0001140361-19-018091-index.htm
2019-10-07Gregory Alan KorbelVP of Business Dev'tBuy500.0015.007,500.00500.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018077/0001140361-19-018077-index.htm
2019-10-07CHRISTIAN S SCHADEPresident & CEOBuy5,000.0015.0075,000.005,000.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018070/0001140361-19-018070-index.htm
2019-10-07JOHN B III HENNEMANDirectorBuy5,000.0015.0075,000.005,000.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018079/0001140361-19-018079-index.htm
2019-10-07Guido MagniDirectorBuy6,500.0015.0097,500.006,500.00https://www.sec.gov/Archives/edgar/data/1781983/000114036119018081/0001140361-19-018081-index.htm
2020-06-165AM Ventures IV, L.P.10% Share HolderSell4,807.0033.30160,073.1075,965.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120037714/0001209191-20-037714-index.htm
2020-06-16SCOTT M ROCKLAGEDirectorSell4,807.0033.30160,073.1075,965.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120037715/0001209191-20-037715-index.htm
2020-06-115AM Ventures IV, L.P.10% Share HolderSell9,800.0028.75281,776.4680,772.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120036845/0001209191-20-036845-index.htm
2020-06-11SCOTT M ROCKLAGEDirectorSell9,800.0028.75281,776.4680,772.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120036847/0001209191-20-036847-index.htm
2020-05-195AM Ventures IV, L.P.10% Share HolderSell10,200.0035.15358,530.0090,572.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120031545/0001209191-20-031545-index.htm
2020-05-19SCOTT M ROCKLAGEDirectorSell10,200.0035.15358,530.0090,572.00https://www.sec.gov/Archives/edgar/data/1781983/000120919120031546/0001209191-20-031546-index.htm